Core Viewpoint - HeartSciences Inc. (HSCS) has shown a downtrend recently, with an 8.3% loss over the past two weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, suggesting that selling pressure may be subsiding [2][5]. - This pattern forms when a stock opens lower, makes a new low, but then closes near or above the opening price, indicating that bulls may be gaining control [4][5]. - Hammer candles can appear on various timeframes and are utilized by both short-term and long-term investors [5]. Fundamental Analysis - There is a strong consensus among Wall Street analysts to raise earnings estimates for HSCS, which supports the bullish case for the stock [2][7]. - The consensus EPS estimate for the current year has increased by 57.4% over the last 30 days, indicating analysts' agreement on the company's improved earnings potential [8]. - HSCS holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2025 HEARTSCIENCES INC. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) Texas 001-41422 26-1344466 (Commission File Number) (IRS Employer Identification No.) FORM 8-K 550 Reserve Street, Suite 360 Southlake, Texas 76092 (Address of Prin ...

Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 (“FQ1 2026”) and provided a business update highlighting continued progress. First Quarter and Recent Highlights HeartSciences has made substantial prog ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41422 HEARTSCIENCES INC. (Exact Name of Registrant as Specified in its Charter) | TEXAS | 26-1344466 | | --- | --- | | ( State or other jurisdiction of | (I.R.S. Em ...

Core Viewpoint - HeartSciences Inc. is actively engaging with investors through multiple virtual events in August 2025 to showcase its AI-powered ECG technology aimed at early heart disease detection [1][2][3] Group 1: Upcoming Events - The company will host an Investor Webinar on August 20, 2025, at 2:00 PM Eastern Time, providing an overview of its mission, market opportunity, and recent progress [2] - HeartSciences will also present at the Emerging Growth Conference 85 on the same day at 3:10 PM Eastern Time, allowing real-time interaction with investors [3] - Archived webcasts of these events will be available for those unable to attend live [4] Group 2: Company Overview - HeartSciences focuses on enhancing the clinical utility of ECGs through innovative AI technology, aiming to improve cardiac screening, especially in frontline clinical settings [5] - The company possesses one of the largest libraries of AI-ECG algorithms and plans to offer these through a cloud-based solution and a low-cost ECG hardware platform [5] - The MyoVista® wavECG™, the company's first product candidate for FDA clearance, is designed to provide diagnostic information related to cardiac dysfunction alongside conventional ECG data [5]

[Form 8-K Current Report: HeartSciences Inc.](index=1&type=section&id=Form%208-K%20Current%20Report%3A%20HeartSciences%20Inc.) [Item 2.02 Results of Operations and Financial Condition](index=3&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) HeartSciences Inc. announced its fiscal year 2025 financial and operating results on July 24, 2025, via a press release furnished as Exhibit 99.1, which is not considered 'filed' for regulatory liability purposes - The company issued a press release on July 24, 2025, to provide financial and operating results for the fiscal year ended April 30, 2025[7](index=7&type=chunk) - The press release is attached as Exhibit 99.1 and is incorporated by reference into this report[7](index=7&type=chunk) - Information in this item and the attached exhibit is not considered "filed" for Section 18 of the Securities Exchange Act of 1934 liability purposes[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=3&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits accompanying the Current Report, primarily the July 24, 2025 press release (99.1) and an Interactive Data File (104) Exhibits Filed | Exhibit No. | Description | | :--- | :--- | | 99.1* | Press Release dated July 24, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

Core Viewpoint - HeartSciences Inc. is advancing its AI-powered ECG technology to enhance heart disease detection and aims for commercialization in 2026, pending regulatory approvals [1][6]. Fiscal 2025 and Business Highlights - The company made significant strategic advancements in fiscal year 2025, focusing on enhancing the clinical value of ECGs through AI and cloud technologies applicable in various healthcare settings [2]. - HeartSciences launched the MyoVista Insights software platform, designed to modernize ECG management and integrate with existing hospital systems, facilitating access to AI-ECG algorithms [6][7]. MyoVista Insights™ Software Platform - MyoVista Insights aims to become the first cloud-native ECG management software, targeting a multibillion-dollar market by replacing outdated systems [6]. - The platform began rollout in May 2025, with plans for a second phase alongside the FDA submission of a cloud-based algorithm for detecting reduced ejection fraction in 2026 [6]. MyoVista® wavECG™ Device - The company is nearing FDA submission for the MyoVista wavECG device, with final testing nearly complete [6]. - The device incorporates an algorithm for impaired cardiac relaxation that aligns with updated guidelines from the American Society of Echocardiography [6]. Financial Results - HeartSciences reported no significant revenue for fiscal year 2025, with approximately $1.1 million in cash and $0.2 million in shareholders' equity as of April 30, 2025 [8]. - The company raised $3.1 million in gross proceeds through a Reg A+ offering and converted $0.9 million of debt into equity, strengthening its balance sheet [11]. Regulatory and Market Developments - The Centers for Medicare & Medicaid Services approved reimbursement for AI-ECG algorithms at $128 per test, in addition to standard ECG reimbursement [6]. - The FDA granted "Breakthrough Device" designation for HeartSciences' aortic stenosis ECG algorithm, indicating significant potential in the market [6]. Intellectual Property and Partnerships - HeartSciences expanded its intellectual property portfolio, holding 44 granted patents worldwide, including a key patent for estimating echocardiographic parameters via ECG [6]. - The company is growing its institutional clinical partnerships and Scientific Advisory Board to support clinical adoption and development [6].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41422 HEARTSCIENCES INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorp ...

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR SystemsSouthlake, TX, June 04, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focused on advancing the capabilities of ECGs/EKGs for the earlier detection of heart disease, today announced that the U.S. Food and Drug Admin ...

Core Insights - HeartSciences Inc. has been granted a foundational patent by the USPTO for estimating echocardiography parameters using an ECG, enhancing its intellectual property portfolio [1] - The company has a total of 44 granted patents, including 10 US patents and 34 international patents across key markets [2] - The CEO of HeartSciences emphasized the strength of their AI-ECG algorithm patent portfolio, positioning the company as a significant player in the AI-ECG field [3] Company Overview - HeartSciences is focused on applying AI technology to ECGs to improve their clinical utility, aiming to enhance cardiac screening, especially in frontline clinical settings [5] - The company possesses one of the largest libraries of AI-ECG algorithms and plans to offer these algorithms through a cloud-based solution and a low-cost ECG hardware platform [5] - The MyoVista® wavECG™, the company's first product candidate for FDA clearance, is designed to provide diagnostic information related to cardiac dysfunction alongside conventional ECG data [5]